CN108348596B - 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 - Google Patents

用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 Download PDF

Info

Publication number
CN108348596B
CN108348596B CN201680050161.9A CN201680050161A CN108348596B CN 108348596 B CN108348596 B CN 108348596B CN 201680050161 A CN201680050161 A CN 201680050161A CN 108348596 B CN108348596 B CN 108348596B
Authority
CN
China
Prior art keywords
bgag
vlp
vlps
virus
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680050161.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN108348596A (zh
Inventor
彼得·普什科
伊丽娜·特蕾娅科娃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medigen Inc
Original Assignee
Medigen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigen Inc filed Critical Medigen Inc
Priority to CN202210931466.8A priority Critical patent/CN115927212A/zh
Publication of CN108348596A publication Critical patent/CN108348596A/zh
Application granted granted Critical
Publication of CN108348596B publication Critical patent/CN108348596B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
CN201680050161.9A 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒 Active CN108348596B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210931466.8A CN115927212A (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02
US62/188,084 2015-07-02
PCT/US2016/040838 WO2017004586A1 (en) 2015-07-02 2016-07-01 Recombinant virus like particles using bovine immunodeficiency virus gag protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210931466.8A Division CN115927212A (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Publications (2)

Publication Number Publication Date
CN108348596A CN108348596A (zh) 2018-07-31
CN108348596B true CN108348596B (zh) 2022-08-23

Family

ID=57609369

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680050161.9A Active CN108348596B (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒
CN202210931466.8A Pending CN115927212A (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202210931466.8A Pending CN115927212A (zh) 2015-07-02 2016-07-01 用牛免疫缺陷病毒Gag蛋白的重组病毒样颗粒

Country Status (13)

Country Link
US (2) US11576965B2 (enExample)
EP (1) EP3316906A4 (enExample)
JP (2) JP6978079B2 (enExample)
KR (1) KR20180032586A (enExample)
CN (2) CN108348596B (enExample)
BR (1) BR112018000037A2 (enExample)
CA (1) CA2991213A1 (enExample)
EA (1) EA201890187A1 (enExample)
MA (1) MA42312A (enExample)
MX (1) MX390927B (enExample)
PE (1) PE20180771A1 (enExample)
RU (2) RU2757723C2 (enExample)
WO (1) WO2017004586A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
CN102676461A (zh) * 2011-03-17 2012-09-19 中国科学院上海巴斯德研究所 一种利用果蝇细胞生产病毒样颗粒的方法及应用
CN102917731A (zh) * 2010-05-26 2013-02-06 西莱克塔生物科技公司 多价的合成纳米载体疫苗

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
EP1576143B1 (en) 2002-05-17 2010-11-24 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20100247574A1 (en) 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
SG10201903161XA (en) 2007-05-29 2019-05-30 Christopher Reid Methods for production and uses of multipotent cell populations
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
WO2015066715A1 (en) 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801412A (zh) * 2007-07-19 2010-08-11 诺瓦瓦克斯股份有限公司 水痘带状疱疹病毒-病毒样颗粒(vlp)和抗原
CN102917731A (zh) * 2010-05-26 2013-02-06 西莱克塔生物科技公司 多价的合成纳米载体疫苗
CN102676461A (zh) * 2011-03-17 2012-09-19 中国科学院上海巴斯德研究所 一种利用果蝇细胞生产病毒样颗粒的方法及应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Analysis of Bovine Leukemia Virus Gag Membrane Targeting and Late Domain Function;Huating Wang等;《JOURNAL OF VIROLOGY》;20020831;第8485-8493页 *
Characterization of Virus-like Particles Produced by a Recombinant Baculovirus Containing the gag Gene of the Bovine Immunodeficiency-like Virus;LYNN RASMUSSEN等;《VIROLOGY》;19901231;第435-451页 *
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures;Peter Pushko等;《Intervirology》;20130416;第141–165页 *
Huating Wang等.Analysis of Bovine Leukemia Virus Gag Membrane Targeting and Late Domain Function.《JOURNAL OF VIROLOGY》.2002, *
Influenza virus-like particles engineered by protein transfer with tumor-associated antigens induces protective antitumor immunity;Jaina M. Patel等;《Biotechnol Bioeng》;20150630;第1102–1110页 *
Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge;Joel R. Haynes等;《Vaccine》;20081119;第530–541页 *

Also Published As

Publication number Publication date
CN108348596A (zh) 2018-07-31
RU2757723C2 (ru) 2021-10-21
JP2020198893A (ja) 2020-12-17
US20230310579A1 (en) 2023-10-05
US12303560B2 (en) 2025-05-20
MA42312A (fr) 2018-05-09
WO2017004586A1 (en) 2017-01-05
MX2018000023A (es) 2018-08-15
RU2020125098A3 (enExample) 2020-12-11
BR112018000037A2 (pt) 2018-09-04
CA2991213A1 (en) 2017-01-05
CN115927212A (zh) 2023-04-07
RU2018103757A (ru) 2019-08-05
JP2018525028A (ja) 2018-09-06
EA201890187A1 (ru) 2018-06-29
RU2020125098A (ru) 2020-09-04
RU2734118C2 (ru) 2020-10-13
US20180369364A1 (en) 2018-12-27
KR20180032586A (ko) 2018-03-30
EP3316906A1 (en) 2018-05-09
RU2018103757A3 (enExample) 2019-12-09
EP3316906A4 (en) 2019-01-02
PE20180771A1 (es) 2018-05-07
HK1259067A1 (zh) 2019-11-22
JP6978079B2 (ja) 2021-12-08
US11576965B2 (en) 2023-02-14
MX390927B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
US12144857B2 (en) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
Tretyakova et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses
Pushko et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
US12303560B2 (en) Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
Kapczynski et al. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses
WO2021150874A1 (en) Recombinant influenza viruses with stabilized na
US10369211B2 (en) Influenza H5 vaccines
WO2018073340A1 (en) Influenza virus vaccine
Pushko et al. Mono-and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model
Hernandez et al. Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs
EP2958586B1 (en) H5 proteins of h5n1 influenza virus for use as a medicament
CN108640981A (zh) H7n9亚型流感病毒重组蛋白及病毒疫苗
HK40090606A (zh) 用牛免疫缺陷病毒gag蛋白的重组病毒样颗粒
HK1259067B (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
Chang et al. Production of immunogenic one-component avian H7-subtype influenza virus-like particles
EA042635B1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
송진하 Generation of recombinant vaccine strains exhibiting enhanced protective responses to H9N2 and H5N1 avian influenza viruses
KR101753978B1 (ko) 고병원성 조류 인플루엔자(h5n1) 및 뉴캣슬병 바이러스 융합 바이러스 유사 입자 백신 및 이를 이용한 백신
Dlugolenski Passage of LPAIV H5 isolates in chickens results in genotypic changes in the glycoprotein genes and development of a species independent competitive ELISA system

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1259067

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment